BMO Capital initiated coverage of Taysha Gene Therapies with an Outperform rating and $5 price target. The company is focused on tackling the $2.5B Rett syndrome opportunity with TSHA-102, a gene therapy, the analyst tells investors. Early data from the low-dose adult and pediatric Phase 1/2 REVEAL trials showed “robust” safety and “promising” signs of efficacy, says the analyst, who says the focus now will be on safety and efficacy data for the high-dose cohort in both trials that is due in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Neurogene negative reaction to competitor data ‘overblown,’ says William Blair
- Taysha Gene Therapies Reports Promising Rett Syndrome Trial Results
- Taysha announces ‘low dose cohort data’ from REVEAL trial for Rett syndrome
Questions or Comments about the article? Write to editor@tipranks.com